Synovial Fibroblast 1: Secretion response of primary human synovial fibroblast samples from one healthy and one rheumatoid arthritis donor to a panel of 10 stimuli and 10 small molecule inhibitors - Dataset (ID:20233)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2159 | IL-17A | 100 | ng/mL | 3 | IFN-a2 | 21.0 | 54 | ||||
RA2159 | PD184352 | 0.1 | uM | IL-17A | 100 | ng/mL | 3 | IFN-a2 | 20.0 | 52 | |
RA2159 | Lestaurtinib | 0.3 | uM | IL-17A | 100 | ng/mL | 3 | IFN-a2 | 23.0 | 50 | |
RA2159 | Ruxolitinib | 0.3 | uM | IL-17A | 100 | ng/mL | 3 | IFN-a2 | 24.0 | 50 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-17A | 100 | ng/mL | 3 | IFN-a2 | 20.0 | 77 | |
RA2159 | IKK16 | 2.0 | uM | IL-17A | 100 | ng/mL | 3 | IFN-a2 | 22.0 | 48 | |
N2586 | IL-17A | 100 | ng/mL | 3 | IFN-a2 | 58.0 | 76 | ||||
N2586 | PD184352 | 0.1 | uM | IL-17A | 100 | ng/mL | 3 | IFN-a2 | 59.0 | 54 | |
N2586 | Lestaurtinib | 0.3 | uM | IL-17A | 100 | ng/mL | 3 | IFN-a2 | 44.0 | 73 | |
N2586 | Ruxolitinib | 0.3 | uM | IL-17A | 100 | ng/mL | 3 | IFN-a2 | 100.0 | 61 | |
N2586 | Tofacitinib | 0.3 | uM | IL-17A | 100 | ng/mL | 3 | IFN-a2 | 43.0 | 61 | |
N2586 | IKK16 | 2.0 | uM | IL-17A | 100 | ng/mL | 3 | IFN-a2 | 39.5 | 44 | |
RA2159 | IL-6 | 100 | ug/mL | 3 | IFN-a2 | 21.0 | 53 | ||||
RA2159 | PD184352 | 0.1 | uM | IL-6 | 100 | ug/mL | 3 | IFN-a2 | 20.0 | 69 | |
RA2159 | Lestaurtinib | 0.3 | uM | IL-6 | 100 | ug/mL | 3 | IFN-a2 | 21.5 | 44 | |
RA2159 | Ruxolitinib | 0.3 | uM | IL-6 | 100 | ug/mL | 3 | IFN-a2 | 16.0 | 65 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-6 | 100 | ug/mL | 3 | IFN-a2 | 18.5 | 64 | |
RA2159 | IKK16 | 2.0 | uM | IL-6 | 100 | ug/mL | 3 | IFN-a2 | 21.0 | 56 | |
RA2159 | Sigma A6730 | 3.0 | uM | 3 | IFN-a2 | 21.5 | 72 | ||||
N2586 | IL-6 | 100 | ug/mL | 3 | IFN-a2 | 52.0 | 57 | ||||
N2586 | PD184352 | 0.1 | uM | IL-6 | 100 | ug/mL | 3 | IFN-a2 | 46.0 | 59 | |
N2586 | Lestaurtinib | 0.3 | uM | IL-6 | 100 | ug/mL | 3 | IFN-a2 | 37.0 | 58 | |
N2586 | Ruxolitinib | 0.3 | uM | IL-6 | 100 | ug/mL | 3 | IFN-a2 | 47.5 | 60 | |
N2586 | Tofacitinib | 0.3 | uM | IL-6 | 100 | ug/mL | 3 | IFN-a2 | 35.0 | 56 | |
N2586 | IKK16 | 2.0 | uM | IL-6 | 100 | ug/mL | 3 | IFN-a2 | 38.0 | 69 |